| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
The primary molecular target of Ftaxilide is not fully characterized, but as an anti-tuberculosis agent, it is likely to target components of the Mycobacterium tuberculosis cell wall or essential metabolic pathways. The compound has antibacterial properties. It is also known to be a sematilide derivative class III antiarrhythmic, suggesting that it may also interact with cardiac ion channels. However, its primary use is as an antituberculosis agent. Further research is needed to fully characterize its molecular targets and mechanism of action.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Ftaxilide is a novel anti-tuberculosis agent with antibacterial activity. It has been shown to be effective against Mycobacterium tuberculosis in vitro. The compound's antibacterial properties make it a promising candidate for the treatment of tuberculosis. It is also used as an antiseptic. The compound's activity is assessed using standard antimicrobial susceptibility testing methods, such as broth microdilution or agar dilution, to determine the minimum inhibitory concentration (MIC) against M. tuberculosis and other bacterial strains.
|
| ln Vivo |
In vivo studies of Ftaxilide are limited, as the compound is primarily used as a research reagent. Its anti-tuberculosis activity suggests potential efficacy in animal models of tuberculosis. However, no extensive in vivo pharmacological or toxicological studies have been reported. The compound is used for research purposes only and is not intended for therapeutic use.
|
| Enzyme Assay |
For antibacterial susceptibility assays, Ftaxilide is tested against Mycobacterium tuberculosis and other bacterial strains using broth microdilution or agar dilution methods to determine the minimum inhibitory concentration (MIC). The compound is dissolved in an appropriate solvent (e.g., DMSO) and serially diluted in growth medium. Bacterial cultures are added to the wells, and the plates are incubated at 37°C for 18-24 hours (or longer for M. tuberculosis). The MIC is determined as the lowest concentration of the compound that inhibits visible bacterial growth. For mechanistic studies, the compound's effect on bacterial cell wall synthesis, protein synthesis, or other essential processes is assessed.
|
| Cell Assay |
For cellular studies, macrophages infected with Mycobacterium tuberculosis are cultured in appropriate medium. Ftaxilide is dissolved in DMSO and diluted in culture medium to final concentrations (typically 0.1-100 µg/mL). Cells are treated with the compound for 24-72 hours. Intracellular bacterial survival is assessed by colony counting after lysing the cells. Cytotoxicity is assessed by MTT or LDH release assays.
|
| Animal Protocol |
For in vivo efficacy studies, animal models of tuberculosis (e.g., mouse aerosol infection model) are used. Ftaxilide is formulated in vehicle and administered orally or intraperitoneally at doses determined from preliminary studies. Bacterial load is measured in lungs and spleen by colony counting. Survival is monitored. Histopathological examination of lungs is performed. For pharmacokinetic studies, blood and tissue samples are collected at various time points for compound quantification by LC-MS.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Ftaxilide are limited, as the compound is a research reagent. As a small molecule with a molecular weight of 269.30, the compound is expected to have moderate oral bioavailability and tissue distribution. Its metabolism likely involves hepatic CYP450 enzymes. However, no dedicated pharmacokinetic studies have been reported.
|
| Toxicity/Toxicokinetics |
Toxicological data for Ftaxilide are limited, as the compound is a research reagent. No acute toxicity, organ-specific toxicity, or mutagenicity data have been reported. As with all research compounds, appropriate safety precautions should be taken when handling Ftaxilide, including the use of personal protective equipment and work in a well-ventilated area.
|
| Additional Infomation |
Ftaxilide (CAS 19368-18-4) is a novel anti-tuberculosis agent. It has a molecular formula of C₁₆H₁₅NO₃ and a molecular weight of 269.30. The compound is a small molecule drug. It has antibacterial properties and is used as an antiseptic. The usage of the INN stem '-ilide' indicates that it is a sematilide derivative class III antiarrhythmic. Ftaxilide is also known as NSC-16112. It is a research tool for studying tuberculosis and is strictly for research use only.
|
| Molecular Formula |
C16H15NO3
|
|---|---|
| Molecular Weight |
269.2952
|
| Exact Mass |
269.105
|
| CAS # |
19368-18-4
|
| PubChem CID |
71895
|
| Appearance |
White to off-white solid powder
|
| Density |
1.262g/cm3
|
| Boiling Point |
375.3ºC at 760mmHg
|
| Flash Point |
180.8ºC
|
| Vapour Pressure |
2.68E-06mmHg at 25°C
|
| Index of Refraction |
1.645
|
| LogP |
3.326
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
20
|
| Complexity |
359
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1=C([H])C([H])=C([H])C([H])=C1C(=O)O[H])N([H])C1C(C([H])([H])[H])=C([H])C([H])=C([H])C=1C([H])([H])[H]
|
| InChi Key |
LLECMGGNFBKPRH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H15NO3/c1-10-6-5-7-11(2)14(10)17-15(18)12-8-3-4-9-13(12)16(19)20/h3-9H,1-2H3,(H,17,18)(H,19,20)
|
| Chemical Name |
2-[(2,6-dimethylphenyl)carbamoyl]benzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 40 mg/mL (~148.53 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7133 mL | 18.5667 mL | 37.1333 mL | |
| 5 mM | 0.7427 mL | 3.7133 mL | 7.4267 mL | |
| 10 mM | 0.3713 mL | 1.8567 mL | 3.7133 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
